Abstract:Life-threatening invasive fungal infections pose a serious threat to human health. A series of novel triazole derivatives bearing a pyrazole-methoxyl moiety were designed and synthesized in an effort to obtain antifungals with potent, broad-spectrum activity that are less susceptible to resistance. Most of these compounds exhibited moderate to excellent in vitro antifungal activities against Candida albicans SC5314 and 10,231, Cryptococcus neoformans 32,609, Candida glabrata 537 and Candida parapsilosis 22,019 with minimum inhibitory concentration (MIC) values of ≤0.125 μg/mL to 0.5 μg/mL. Use of recombinant Saccharomyces cerevisiae strains showed compounds 7 and 10 overcame the overexpression and resistant-related mutations in ERG11 of S. cerevisae and several pathogenic Candida spp. Despite being substrates of the C. albicans and Candida auris Cdr1 drug efflux pumps, compounds 7 and 10 showed moderate potency against five fluconazole (FCZ)-resistant fungi with MIC values from 2.0 μg/mL to 16.0 μg/mL. Growth kinetics confirmed compounds 7 and 10 had much stronger fungistatic activity than FCZ. For C. albicans, compounds 7 and 10 inhibited the yeast-to-hyphae transition, biofilm formation and destroyed mature biofilm more effectively than FCZ. Preliminary mechanism of action studies showed compounds 7 and 10 blocked the ergosterol biosynthesis pathway at Erg11, ultimately leading to cell membrane disruption. Further investigation of these novel triazole derivatives is also warranted by their predicted ADMET properties and low cytotoxicity.

Synthesis, in Vitro Evaluation and Molecular Docking Studies of New Triazole Derivatives As Antifungal Agents.

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives Containing the 1,2,3-Triazole Group

Design, Synthesis and Molecular Docking Studies of Novel Triazole Antifungal Compounds

Synthesis, In Vitro Biological Evaluation, and Molecular Docking of New Triazoles as Potent Antifungal Agents.

Design, synthesis, and antifungal activity of novel conformationally restricted triazole derivatives.

Synthesis, Molecular Docking, and Biological Evaluation of Novel Triazole Derivatives as Antifungal Agents

Design, Synthesis, and Antifungal Activities of Novel 1H-Triazole Derivatives Based on the Structure of the Active Site of Fungal Lanosterol 14α-Demethylase (CYP51)

Design, synthesis, and antifungal activities of novel 1H-triazole derivatives based on the structure of the active site of fungal lanosterol 14 alpha-demethylase (CYP51).

Synthesis, antifungal activity, and molecular docking studies of novel triazole derivatives.

Molecular Docking, Design, Synthesis and Antifungal Activity Study of Novel Triazole Derivatives

Design, Synthesis and Antifungal Evaluation of 1-(2-(2,4-Difluorophenyl)-2-hydroxy-3-(1h-1,2,4-triazol-1-yl)propyl)-1h-1,2,4-triazol-5(4h)-one

Design, Synthesis, and Biological Evaluation of Novel Triazole Derivatives As Inhibitors of Cytochrome P450 14Α-Demethylase.

Design, synthesis and antifungal activities of novel 1,2,4-triazole derivatives.

Synthesis and antifungal evaluation of novel triazole derivatives bearing a pyrazole-methoxyl moiety

Design, synthesis and <i>in vitro</i> biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Design, synthesis and molecular docking studies of novel triazole as antifungal agent.

Synthesis and antifungal activity of the novel triazole compounds

Synthesis of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase (CYP51).

Design, synthesis and in vitro biological studies of novel triazoles with potent and broad-spectrum antifungal activity

Structure-based design, synthesis, and antifungal activity of new triazole derivatives.

Design, Synthesis, and in Vitro Evaluation of Novel Triazole Analogues Featuring Isoxazole Moieties As Antifungal Agents.